Abstract

Since its first introduction approximately 10 years ago, there has been extensive progress in the application of magnetic resonance imaging (MRI) to the detection and diagnosis of breast cancer. Contrast-enhanced MRI has been shown to have value in the diagnostic work-up of women who present with mammogram or clinical abnormalities. In addition, it has been demonstrated that MRI can detect mammogram occult multifocal cancer in patients who present with unifocal disease. Advances in risk stratification and limitations in mammography have stimulated interest in the use of MRI to screen high-risk women for cancer. Several studies of MRI high-risk screening are ongoing. Preliminary results are encouraging.

Highlights

  • It is estimated that approximately one in nine women will develop breast cancer in her lifetime

  • The ability of mammography screening to reduce breast cancer mortality rates was demonstrated by several studies performed in the US and Europe [3,4,5]

  • It is generally accepted that careful screening with mammography will reduce the breast cancer mortality rate in a given population

Read more

Summary

Introduction

It is estimated that approximately one in nine women will develop breast cancer in her lifetime. It is generally accepted that a combination of architectural and kinetic features should be used for differentiating benign from malignant breast lesions The use of these features in a diagnostic population will have performance similar to that described in the model reported by Nunes et al [23]. In a study reported by Orel et al [29], MRI detected the primary lesion in 85% of women who presented with positive axillary nodes, and negative mammography and clinical examinations. MRI detected all nine cancers; this included five cancers that were occult to mammography + ultrasound These results, very preliminary, clearly demonstrate great potential for MRI in increasing the yield of screening high-risk women

Conclusion
National Institutes of Health Consensus Development Conference Statement
34. Office on Women Health: Technical Report
Findings
37. Boetes C

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.